Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression.

Slides:

Advertisements

Similar presentations

Supplementary Figure S1.

Advertisements

A Untreated mM maphos, 48h 20 mM maphos, 48h 50 mM maphos, 48hh B

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer by Ou Cao, Eric Dobrzynski,

Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.

Volume 24, Issue 11, Pages (November 2016)

by Norman Nausch, Ioanna E

Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy by Fumihiko Tsushima, Sheng Yao, Tahiro Shin, Andrew Flies, Sarah.

The role of CC chemokine receptor 5 in antiviral immunity

by Jamie Honeychurch, Alison L. Tutt, Thomas Valerius, Ingmar A. F. M

Sunitinib plus rMVA–CEA–TRICOM vaccine decreased tumor burden and increased intratumoral infiltration of T lymphocytes in the MC38-CEA colon carcinoma.

IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis

by Bindu Varghese, Adam Widman, James Do, Behnaz Taidi, Debra K

CD1dhiCD5+ B cells are expanded in pancreatic neoplasia and are functionally important for sustaining growth of KrasG12D-PDEC in vivo. CD1dhiCD5+ B cells.

Volume 19, Issue 8, Pages (August 2011)

Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing.

The PI3K–Akt pathway is essential for the in vivo maintenance of murine Tregs. The PI3K–Akt pathway is essential for the in vivo maintenance of murine.

IL-6 is dispensable for the suppressive activity of MDSC on primary CD4+ T-cell activation. IL-6 is dispensable for the suppressive activity of MDSC on.

Gr-1+ MDSC in tumor-bearing mice produce IL-6.

SKAP55‐deficient mice enhance DC‐based vaccine for prevention of tumors in vivo AWT and SKAP55 KO C57BL/6 mice were s.c. immunized on day −14 and day −7.

Volume 19, Issue 3, Pages (March 2011)

Activating anti-CD40 antibody partially mitigates the deficit in CTL generation and accumulation elicited by immunization with F/T 4T1-OVA cells. Activating.

Administration of pIL2 and pgDE7 induces higher activation of E7-specific Tem CD8+ T cells. Administration of pIL2 and pgDE7 induces higher activation.

Volume 18, Issue 3, Pages (March 2003)

Interleukin-18 and the Costimulatory Molecule B7-1 Have a Synergistic Anti-Tumor Effect on Murine Melanoma; Implication of Combined Immunotherapy for.

Exosomes from M1-Polarized Macrophages Potentiate the Cancer Vaccine by Creating a Pro-inflammatory Microenvironment in the Lymph Node Lifang Cheng,

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Volume 19, Issue 9, Pages (May 2017)

Volume 24, Issue 1, Pages (January 2016)

Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Volume 7, Issue 2, Pages (August 1997)

Volume 17, Issue 5, Pages (May 2009)

Anti-SEMA4D and anti–CTLA-4 treatment is synergistic and increases the frequency of tumor-specific TILs and secretion of proinflammatory cytokines, while.

Antigen-specific immune responses are enhanced in hypertension.

Volume 25, Issue 4, Pages (April 2017)

PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.

Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response Arup Garu, Gopikrishna.

CT-26 colon cancer induces the recruitment of protumor mast cells and the accumulation of MDSCs. CT-26 colon carcinoma cells (2 × 105) were injected s.c.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

GC reaction is impaired in NOTCH2 knock-in mice.

Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but not OVA Augmentation of in vivo CMS5mHE tumor eradication by HER216-30, but.

Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. Mitotic catastrophe symptoms caused by curcumin are followed by apoptosis. A.

Immunization regimens that include a GLA-SE-formulated protein vaccine generate memory CD4 T cells. Immunization regimens that include a GLA-SE-formulated.

Matriptase-2 inhibited breast tumor development in vivo.

Depletion of UCP1 and Myf5 population reduced xenograft growth.

MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting Sox2. MiR-200c suppresses tumor growth and metastasis of CRC in vivo by targeting.

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

Induction of a tumor-specific immune response following radiofrequency ablation (RFA). Induction of a tumor-specific immune response following radiofrequency.

Uptake of TEX by DCs in vivo.

Deletion of Tgfbr2 in myeloid cells elevated IFN-γ production in CD8+ T cells, and systemic IFN-γ neutralization diminished metastasis inhibition in Tgfbr2MyeKO.

B- and T-cell activity induced by immunization.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

SPARC is required for spontaneous metastasis

Memory CD8+ T Cells Undergo Peripheral Tolerance

Cross-presentation of ova to ova-specific CD8+ T cells in vivo by ova-loaded gp96 surface-expressing tumor cells. Cross-presentation of ova to ova-specific.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice.

LSECtin, expressed by B16 cells, inhibits the tumor-specific immune responses both in vivo and in vitro. LSECtin, expressed by B16 cells, inhibits the.

Hypoxia upregulates CD137 expression in T lymphocytes undergoing activation. Hypoxia upregulates CD137 expression in T lymphocytes undergoing activation.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

The effect of βAR signaling on the generation of a cytotoxic CD8+ T-cell response in vivo. The effect of βAR signaling on the generation of a cytotoxic.

Volume 25, Issue 4, Pages (April 2017)

Immunization with F/T cells elicits CTLs with moderate and transient effector function. Immunization with F/T cells elicits CTLs with moderate and transient.

Lnc-C/EBPβ negatively regulates immune-suppressive function of MDSCs in vivo. Lnc-C/EBPβ negatively regulates immune-suppressive function of MDSCs in vivo.

MDSC population in patient peripheral blood.

Expression of CAR, endogenous TCR, and target-cell receptors.

Presentation transcript:

Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression. Anti–TGF-β1 antibody neutralizes APB-mediated immune suppression. A, tetramer staining assay. Six days after immunization of mice with DCOVA, or DCOVA plus APB, or DCOVA plus APB and anti–TGF-β1 or control antibody (Ab), the tail blood samples were taken from the immunized mice, stained with PE-H-2Kb/OVA I peptide tetramer and FITC-anti-CD8 antibody, and analyzed by flow cytomery. The value in each panel represents the percentage of tetramer-positive CD8+ T cells versus the total CD8+ T-cell population. The value in parenthesis represents the SD. *, P < 0.05 versus cohorts of APB (Student's t test). B, in vivo cytotoxicity assay. The OVA I and Mut1 peptide–pulsed CFSEhigh and CFSElow target cells were i.v. injected at 1:1 ratio into the above immunized mice 6 d after the above immunizations. Sixteen hours later, the splenocytes of immunized mice were analyzed by flow cytometry. The value in each panel represents the percentage of CFSEhigh versus CFSElow target cells remaining in the spleen. The value in parenthesis represents the SD. *, P < 0.05 versus cohorts of APB (Student's t test). C, animal studies. C57BL/6 mice were s.c. vaccinated with DCOVA, or DCOVA plus APB, or DCOVA plus APB and anti–TGF-β1 or control antibody. Eight days after immunization, the immunized mice were s.c. inoculated with EG7 tumor cells. Animal mortality and tumor growth were monitored daily for up to 60 d. One representative experiment of two is shown. Yufeng Xie et al. Cancer Res 2009;69:7756-7766 ©2009 by American Association for Cancer Research